Kynexis Launched to Advance Precision Therapeutics for Brain Diseases
07 nov. 2023 05h00 HE
|
Kynexis
- Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor, Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia - €57 Million Series A Led by Forbion ...
Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration
31 oct. 2023 07h00 HE
|
Verge Genomics
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today...
Schizophrenia Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Otsuka, Boehringer Ingelheim, Merck, Sunivion, PsychoGenics, Neurocrine Biosciences, Takeda, Lyndra, Cerevel
17 oct. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Schizophrenia Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Otsuka, Boehringer Ingelheim,...
The Future of Global Mental Health Management Research Report 2023: Complementing Prescription Therapies with AI/ML/VR for Better Outcomes to Become More Prominent
20 juil. 2023 05h38 HE
|
Research and Markets
Dublin, July 20, 2023 (GLOBE NEWSWIRE) -- The "The Future of Mental Health Management" report has been added to ResearchAndMarkets.com's offering. This report identifies the challenges, drivers,...
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
28 juin 2023 08h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Schizophrenia Drugs Market Size to Witness Healthy Valuation of US$ 12.6 Billion at 5.6% CAGR by 2032 | Market.us Report
25 mai 2023 07h54 HE
|
Market.Us
New York, May 25, 2023 (GLOBE NEWSWIRE) -- As per this latest study by Market.us, The global Schizophrenia Drugs Market was valued at US$ 7.4 Bn in 2022. It is projected to expand at a CAGR of 5.6%...
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
15 mai 2023 07h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
10 mai 2023 08h00 HE
|
Minerva Neurosciences, Inc
FDA confirms acceptance of the filing of the NDA for roluperidone Application has been granted a standard review FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26,...
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
08 mai 2023 08h30 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
01 mai 2023 07h00 HE
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...